Orexo AB has announced promising pharmacokinetic in-vivo data for its intranasal semaglutide formulation, developed using the AmorphOX technology. In a comparative study, the AmorphOX powder formulations demonstrated a sevenfold increase in plasma levels compared to the oral semaglutide tablet, Rybelsus, while exhibiting lower variability than the injectable form, Wegovy.
This data reinforces the potential of AmorphOX to enable large molecules to be effectively delivered intranasally, offering a needle-free alternative that enhances patient convenience and adherence. The implications extend to dosing schedules, which may become less frequent than those required for oral administration, thereby improving patient compliance.
Robert Rönn, SVP and Head of R&D, emphasized that the successful formulation of semaglutide using AmorphOX could lead to strategic partnerships aimed at expanding this innovative delivery method. With Orexo’s established expertise in proprietary formulation technologies, the company is well-positioned to address significant medical needs, particularly in the treatment of type 2 diabetes and obesity.
As the pharmaceutical landscape evolves, the development of intranasal GLP-1 receptor agonists could disrupt current treatment paradigms, offering a more convenient and potentially more effective therapeutic option for patients.
